vs
Side-by-side financial comparison of GREENPOWER MOTOR Co INC. (GP) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.2M, roughly 1.3× GREENPOWER MOTOR Co INC.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -65.6%, a 5.3% gap on every dollar of revenue. On growth, GREENPOWER MOTOR Co INC. posted the faster year-over-year revenue change (-11.5% vs -49.9%).
GreenPower Motor Company Inc. is a Canadian electric bus manufacturer and distributor in North America. The company fabricates multiple zero-emission models, including transit buses, school buses, and double decker buses. GreenPower headquarters are in Vancouver, British Columbia, with a sales office in Rancho Cucamonga, California; an assembly facility in Porterville, California; and a production facility in South Charleston, West Virginia. Its stock is traded on Nasdaq the United States.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
GP vs PLX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.2M | $9.1M |
| Net Profit | $-4.7M | $-5.5M |
| Gross Margin | 14.6% | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | -65.6% | -60.3% |
| Revenue YoY | -11.5% | -49.9% |
| Net Profit YoY | -2.1% | -184.8% |
| EPS (diluted) | $-0.17 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | $7.2M | $18.2M | ||
| Q3 24 | $5.3M | $18.0M | ||
| Q2 24 | $3.0M | $13.5M | ||
| Q4 23 | $8.2M | $10.5M |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | $-4.7M | $6.5M | ||
| Q3 24 | $-4.7M | $3.2M | ||
| Q2 24 | $-5.4M | $-2.2M | ||
| Q4 23 | $-4.6M | $-6.0M |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | 14.6% | 78.7% | ||
| Q3 24 | 8.6% | 53.4% | ||
| Q2 24 | 7.4% | 29.8% | ||
| Q4 23 | 16.6% | 15.5% |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | -65.6% | 35.6% | ||
| Q3 24 | -87.9% | 18.0% | ||
| Q2 24 | -179.8% | -16.4% | ||
| Q4 23 | -56.9% | -57.6% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | $-0.17 | $0.10 | ||
| Q3 24 | $-0.18 | $0.03 | ||
| Q2 24 | $-0.21 | $-0.03 | ||
| Q4 23 | $-0.19 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $621.1K | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1M | $48.2M |
| Total Assets | $37.4M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | $621.1K | $19.8M | ||
| Q3 24 | $116.9K | $27.4M | ||
| Q2 24 | $528.3K | $23.4M | ||
| Q4 23 | $4.0M | $23.6M |
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | $2.1M | $43.2M | ||
| Q3 24 | $4.2M | $32.4M | ||
| Q2 24 | $8.6M | $28.6M | ||
| Q4 23 | $18.1M | $33.6M |
| Q4 25 | — | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | $37.4M | $73.4M | ||
| Q3 24 | $39.4M | $61.6M | ||
| Q2 24 | $43.5M | $91.5M | ||
| Q4 23 | $50.2M | $84.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | $-1.1M | $4.0M | ||
| Q3 24 | $-1.3M | $4.1M | ||
| Q2 24 | $-3.2M | $-3.6M | ||
| Q4 23 | $1.4M | $3.6M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GP
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
